Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833469 | 1.00 | CES2 (0.53) | CES2CES1KMT2AMAPTPKM | |
| SCHEMBL11218903 | 1.00 | CES2 (0.53) | CES2CES1KMT2AMAPTPKM | |
| SCHEMBL6836014 | 0.88 | MEN1 (0.53) | CES2CES1KMT2AMAPTPKM | |
| SCHEMBL11224523 | 0.88 | MEN1 (0.53) | CES2CES1KMT2AMAPTPKM | |
| SCHEMBL6836012 | 0.88 | MEN1 (0.53) | CES2CES1KMT2AMAPTPKM | |
| SCHEMBL1070286 | 0.85 | MEN1 (0.53) | KMT2AMAPTALDH1A1MEN1RAB9A | |
| SCHEMBL6831082 | 0.84 | KMT2A (0.56) | CES2CES1KMT2AMAPTPKM | |
| SCHEMBL8999201 | 0.83 | NPC1 (0.50) | CES2CES1KMT2AMAPTALDH1A1 | |
| SCHEMBL8999208 | 0.83 | NPC1 (0.50) | CES2CES1KMT2AMAPTALDH1A1 | |
| SCHEMBL9337350 | 0.82 | MAPT (0.52) | CES1KMT2AMAPTPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| WO-2014031755-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20040029928-A1 | Novel propenohydroxamic acid derivatives | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1314721-A1 | NOVEL PROPENOHYDROXAMIC ACID DERIVATIVES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-5880284-A | HAVING ANTITHROMBOTIC, ANTIAGGREGATORY AND TUMOR- OR METASTASES-INHIBITING EFFECTS | DR. KARL THOMAE GMBH (DE) | 1999-03-09 | — | — | US | disclosed |
| US-5827849-A | HAVING INHIBITORY EFFECT ON INFLAMMATION AND BONE DEGRADATION, ANTITHROMBOTIC, ANTIAGGREGATORY AND TUMOR- OR METASTASIS-INHIBITING EFFECT | KARL THOMAE GMBH (DE) | 1998-10-27 | — | — | US | disclosed |
| US-5681841-A | PREVENTION CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| US-5612335-A | ANTICOAGULANTS; COMBATING/PREVENTING DISEASES WHERE CELL AGGREGATES OCCUR OR CELL-MATRIX INTERACTIONS PLAY A PART | KARL THOMAE GMBH (DE) | 1997-03-18 | — | — | US | disclosed |
| US-5519036-A | IMIDAZOLIDINONES, ANTICOAGULANTS, CELL AGGREGATION PREVENTION | KARL THOMAE GMBH (DE) | 1996-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029928-A1 | Novel propenohydroxamic acid derivatives | TNF, SI, HDGF | CES2 3108/4885CES1 437/4885KMT2A 3817/4885 |
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | KRAS, RASSF5, RASSF2 | CES2 1093/4885CES1 344/4885KMT2A 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.